OJJAARA Market Summary

Key Factors Driving OJJAARA Growth

1. First and only JAK inhibitor specifically indicated for myelofibrosis patients with anemia

OJJAARA (momelotinib) is the first and only FDA-approved JAK inhibitor specifically indicated for adults with intermediate- or high-risk myelofibrosis (primary or secondary) with anemia, irrespective of prior JAK inhibitor exposure. Since approximately 40% of patients are anemic at diagnosis and nearly all develop anemia during disease progression, the drug addresses a major unmet clinical need that frequently limits treatment with other JAK inhibitors. This differentiated positioning is expected to drive increasing adoption among hematologists treating transfusion-dependent or symptomatic patients.

2. Strong Phase III efficacy across anemia, spleen response, and symptom control

OJJAARA's approval was supported by the pivotal MOMENTUM and SIMPLIFY-1 Phase III trials. In the MOMENTUM study involving previously JAK inhibitor-treated anemic patients, 30% of patients receiving momelotinib achieved transfusion independence versus 20% with danazol, while 39% achieved at least a 25% reduction in spleen volume compared with 6% for danazol. Additionally, 25% of patients achieved a ≥50% reduction in total symptom score versus 9% with danazol. These clinically meaningful improvements across all three major disease manifestations differentiate OJJAARA from competing therapies.

3. Differentiated mechanism of action expands physician confidence

OJJAARA inhibits JAK1, JAK2, and ACVR1 (activin A receptor type 1). ACVR1 inhibition suppresses hepcidin production, thereby improving iron availability and erythropoiesis, which contributes to reduced transfusion requirements and anemia improvement. This unique mechanism enables simultaneous management of anemia, splenomegaly, and constitutional symptoms, providing an important therapeutic advantage over existing JAK inhibitors that may worsen anemia. The differentiated pharmacology is expected to support broader use in both frontline and previously treated patients.

4. Expanding global regulatory approvals increase commercial opportunity

Following its US FDA approval in September 2023, OJJAARA has rapidly expanded internationally with approvals from the European Commission, the UK Medicines and Healthcare products Regulatory Agency (MHRA), and Japan's Ministry of Health, Labour and Welfare (MHLW) in 2024. These approvals allow GSK to commercialize the drug across all major hematology markets and significantly enlarge the addressable patient population beyond the United States.

5. Growing treatment adoption supported by clinical guidelines and unmet need

Clinical evidence from the MOMENTUM and SIMPLIFY-1 trials has positioned OJJAARA as an important treatment option for myelofibrosis patients with moderate-to-severe anemia, a population historically underserved by existing JAK inhibitors. Health technology assessment agencies and reimbursement bodies have recognized its benefits in improving transfusion independence alongside spleen and symptom responses, supporting broader reimbursement and physician adoption across major markets. Continued real-world experience is expected to further strengthen utilization.

OJJAARA Recent Developments

In September 2025, GSK announced a letter of intent with the pan-Canadian Pharmaceutical Alliance for Ojjaara (momelotinib) to expand public funding access for myelofibrosis patients with anemia. Additionally, GSK reported that momelotinib received Orphan Drug Designations in the US and EU for VEXAS syndrome.

“OJJAARA Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of OJJAARA for approved indication like Myelofibrosis; as well as potential indication like Myelodysplastic syndromes, VEXAS syndrome, and Acute myeloid leukaemia in the 7MM. A detailed picture of OJJAARA’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the OJJAARA for approved and potential indications. The OJJAARA market report provides insights about OJJAARA’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current OJJAARA performance, future market assessments inclusive of the OJJAARA market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of OJJAARA sales forecasts, along with factors driving its market.

OJJAARA Drug Summary

OJJAARA (Momelotinib) is an oral Janus kinase (JAK) 1, JAK2, and activin A receptor type 1 (ACVR1) inhibitor approved for the treatment of adults with intermediate- or high-risk primary or secondary myelofibrosis accompanied by anemia, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. OJJAARA works by inhibiting dysregulated JAK signaling to reduce splenomegaly and constitutional symptoms while also suppressing ACVR1-mediated hepcidin production, thereby improving iron availability and addressing disease-related anemia. Administered orally once daily, OJJAARA demonstrated significant reductions in spleen volume, improvements in symptom burden, and enhanced transfusion independence in pivotal clinical trials, including the MOMENTUM and SIMPLIFY studies. Common adverse events include thrombocytopenia, diarrhea, dizziness, nausea, fatigue, and elevated liver enzymes, and patients should be monitored for hematologic toxicities, infections, and hepatic function during treatment. Approved by the U.S. FDA in 2023, OJJAARA is the first JAK inhibitor specifically indicated for myelofibrosis patients with anemia, providing a differentiated therapeutic option for a population with substantial unmet clinical needs. The report provides OJJAARA’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the OJJAARA Market Report

The report provides insights into:

• A comprehensive product overview including the OJJAARA MoA, description, dosage and administration, research and development activities in approved indications like Myelofibrosis; as well as potential indication like Myelodysplastic syndromes, VEXAS syndrome, and Acute myeloid leukaemia.
• Elaborated details on OJJAARA regulatory milestones and other development activities have been provided in OJJAARA market report.
• The report also highlights OJJAARA‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The OJJAARA market report also covers the patents information, generic entry and impact on cost cut.
• The OJJAARA market report contains current and forecasted OJJAARA sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The OJJAARA market report also features the SWOT analysis with analyst views for OJJAARA in approved and potential indications.

Methodology

The OJJAARA market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

OJJAARA Analytical Perspective by DelveInsight

• In-depth OJJAARA Market Assessment

This OJJAARA sales market forecast report provides a detailed market assessment of OJJAARA for approved indication like Myelofibrosis; as well as potential indication like Myelodysplastic syndromes, VEXAS syndrome, and Acute myeloid leukaemia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted OJJAARA sales data uptil 2034.

• OJJAARA Clinical Assessment

The OJJAARA market report provides the clinical trials information of OJJAARA for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

OJJAARA Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

OJJAARA Market Potential & Revenue Forecast

• Projected market size for the OJJAARA and its key indications
• Estimated OJJAARA sales potential (OJJAARA peak sales forecasts)
• OJJAARA Pricing strategies and reimbursement landscape

OJJAARA Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• OJJAARA Market positioning compared to existing treatments
• OJJAARA Strengths & weaknesses relative to competitors

OJJAARA Regulatory & Commercial Milestones

• OJJAARA Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

OJJAARA Clinical Differentiation

• OJJAARA Efficacy & safety advantages over existing drugs
• OJJAARA Unique selling points

OJJAARA Market Report Highlights

• In the coming years, the OJJAARA market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The OJJAARA companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence OJJAARA’s dominance.
• Other emerging products for Myelofibrosis; as well as potential indication like Myelodysplastic syndromes, VEXAS syndrome, and Acute myeloid leukaemia are expected to give tough market competition to OJJAARA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of OJJAARA in approved and potential indications.
• Analyse OJJAARA cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted OJJAARA sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of OJJAARA in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of OJJAARA? How strong is OJJAARA’s clinical and commercial performance?
• What is OJJAARA’s clinical trial status in each individual indications such as Myelofibrosis; as well as potential indication like Myelodysplastic syndromes, VEXAS syndrome, and Acute myeloid leukaemia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the OJJAARA Manufacturers?
• What are the key designations that have been granted to OJJAARA for approved and potential indications? How are they going to impact OJJAARA’s penetration in various geographies?
• What is the current and forecasted OJJAARA market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of OJJAARA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to OJJAARA for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is OJJAARA? What is the duration of therapy and what are the geographical variations in cost per patient?